6th Annual IPO Report

2021 Australian IPO Activity OnMarket

IPOs returned an average of 15.2% for 2021, outperforming the ASX200 by 2.1%.

OnMarket 2021 IPO Report

OnMarket is pleased to release the 6th Annual IPO Report - detailing 2021 IPO activity and providing insight into the Australian IPO Market for 2022.

For regular readers it won’t surprise you that our message is the same as other years. 2021 IPOs have yet again outperformed the market with an average end of year return of 15.2%, outperforming the ASX 200 by 2.1%. 

2021 was a record year for the number of IPOs on ASX, with a total of 204 IPOs on the ASX raising a combined $13.4b. An increase from $5.6b across 79 listings in 2020.

Throughout the first half of the year, there were 67 new listings. Investors in H1 were rewarded, with H1 IPOs outperforming the ASX 200 by 9.3% come 31 December. In H2, IPO volume surged, with 67% of 2021 IPOs occurring in the second half of the year, raising almost 74% of the total capital raised in 2021. 

To download the 2021 IPO Report, or IPO reports from the last 5 years, please follow the links below.



The OnMarket Team


Discover investment opportunities here.


Equity Crowdfunding Live

Neutrog Limited

Leading producer of optimum performing biological and organic fertilisers


Over 35 years, Neutrog have grown into a premium brand with a high level of market visibility and trust.


Having commenced operations in 1988 and transformed from organic to biological fertilisers, Neutrog is hardly an overnight success story. 


Before investing please consider the offer document and the general risk warning.

Minimum target reached - Overfunding







Wholesale (SAFE) Live

Stropro Technologies Pty Ltd

Stropro Technologies Pty Ltd
Market-leading and award-winning alternatives investment platform


With a mission to inspire investors to adopt a global multi-asset approach to wealth management, Stropro offers curated investments from global investment banks and a range of alternative fund managers across Structured Investments, Private Debt, Impact/ESG, Venture Capital, Cryptocurrency and more.


This is a wholesale offer and only open to professional, sophisticated and experienced investors. More info here

Up to $2 millionSize of Offer
17 May 22Offer Open
07 Jun 22Pay By
Equity Crowdfunding Upcoming

BookitDoit Pty Ltd

BookitDoit Pty Ltd
Rediscovering hidden Australia. Redefining domestic travel


BookitDoit’s Regional Australian booking platform aggregates thousands of experiences across all regions, states, and territories - filling the virtual gap and enabling Aussies and international visitors to findbook, and do the authentic experiences ‘real Australia’ has to offer. 


Before investing please consider the offer document and the general risk warning.

Equity Crowdfunding Upcoming

Mrs Clucks Pty Ltd

Mrs Clucks Pty Ltd
Community-based – open paddock hens - naturally healthier eggs


Consumers demanded and supermarkets responded taking cage eggs off shelves from 2025.


Mrs Clucks – producer of open-paddock, true free-range eggs - got cracking, proved the commercial viability of egg production using sustainable farming methods for a healthier environment.


Before investing please consider the offer document and the general risk warning.

Equity Crowdfunding Upcoming

Spatial Hub Analytics Pty Ltd

Spatial Hub Analytics Pty Ltd
Converting Geo-data into commercial solutions


Spatial Hub's Geospatial AI tool turns environmental data into solutions that relate to where we live, work, and elements that we interact with.


What makes them unique is how they layer this data over time and use learnings from history to make better future decisions.


Before investing please consider the offer document and the general risk warning.

Wholesale Closed May 2022

Respien Pty Ltd

Respien Pty Ltd

Respien Pty Ltd is an Australian clinical stage drug development company targeting the top 5 cause of death global - chronic lung conditions (like chronic bronchitis & emphysema, collectively called COPD). With Covid dramatically increasing COPD, the company believes it can disrupt the multi-billion dollar COPD pharma care industry with its three clinically tested, better performing products.

Fully Funded
150000Size of Offer
N/A Lead Manager